PPT-Diagnosis, Prevention and Management of Statin

Diagnosis Prevention and Management of Statin Adverse Effects and Intolerance Canadian Consensus Working Group Update 2016 GB John Mancini MD Steven Baker MD Jean Bergeron MD David Fitchett MD Jiri Frohlich MD Jacques. Louis H. Stein, Jessica Berger, Maryann . Tranquilli. , . John A. . Elefteriades. .. . The Aortic Institute at Yale – New Haven Hospital . Bench top to bedside interaction. . Medial Degeneration . Nice Guidelines . Who to offer therapy to?. Offer . lipid-modification . therapy. to. people aged 84 years and younger if their estimated 10-year risk of developing cardiovascular disease (CVD) using the . Canadian Consensus . Working Group Update (2016). G.B. John Mancini, MD, Steven Baker, MD, Jean Bergeron, MD, David Fitchett, MD, . Jiri Frohlich, MD, Jacques Genest, MD, Milan Gupta, MD, Robert A. Hegele, MD, . Under-Representation of Women . in Clinical Trials. CVD in Women. Women. ’. s CV Risk is Often Misunderstood or Misdiagnosed. Gender Disparities in Screening, Diagnosis, and Treatment of Dyslipidemia. DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. common goal. a. common goal. “These guidelines are meant to define practices that meet the needs of patients in most circumstances and are not a replacement for clinical judgment. The ultimate decision about care of a particular patient must be made by the healthcare provider and patient in light of the circumstances presented by that patient. As a result, situations might arise in which deviations from these guidelines may be appropriate. These considerations notwithstanding, in caring for most patients, clinicians can employ the recommendations confidently to reduce the risks of atherosclerotic cardiovascular disease (ASCVD) events.”. James J. Lehman, DC, MBA, FACO. Associate Professor of Clinical Sciences. School of Chiropractic. Director. Community Health Clinical Education. University of Bridgeport. Learning Objectives. . Organize a clinical thought process while performing a neuromusculoskeletal evaluation of a patient with statin myopathy and piriformis syndrome.. Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016) G.B. John Mancini, MD, Steven Baker, MD, Jean Bergeron, MD, David Fitchett, MD, Purpose. Outline highlights from the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Review statin management in high risk patients. 2. ACC/AHA 2018: Overall Approach. Assess risk, determine management group. Control. Relative risk. Absolute Effect. (per thousand). Statin. Myalgia. 348/14960. (2.3%) . 288/14520. (2.0%). 1.02. (0.88-1.19). +1. (-1 to +5). Rhabdomyolysis. 138/2454. (5.6%). 158/2446. (6.5%). . Rabizadeh. , . MD. .. Imam . Khomeini . Medical . Complex,. Tehran . University of Medical Sciences. Introduction. Statin . use has . increased progressively in all age groups since . 1988 . The . Outline the issue of medication nonadherence and reasons that patients may not adhere to medications (with a particular focus on statin). Review strategies to improve patient adherence to statins. 2. of the NLA. Conclusions of the NLA Safety Task Force for Muscle Safety. Myopathy and rhabdomyolysis are associated with statin therapy, as a class effect. Elevated creatine kinase (CK) levels may indicate statin-induced muscle damage. Alfred Fisher MD PhD. Professor and Chief. Division of Geriatrics, Gerontology,. and Palliative Medicine. University of Nebraska Medical Center. Older Patients in Primary Care often take Statins. Johansen, et. al. . Slide deck. The full text of the paper is available at. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31652-0/fulltext. . Rationale. Lipoprotein. (a) . is. an . established. . risk.